Interferon Regulatory Factor 9 Promotes Lung Cancer Progression via Regulation of Versican.
adenocarcinoma
interferon regulatory factor 9 (IRF9)
lung cancer
tumor microenvironment (TME)
type I interferons (IFNs)
versican (VCAN)
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
08 Jan 2021
08 Jan 2021
Historique:
received:
13
11
2020
revised:
30
12
2020
accepted:
02
01
2021
entrez:
12
1
2021
pubmed:
13
1
2021
medline:
13
1
2021
Statut:
epublish
Résumé
Transcription factors can serve as links between tumor microenvironment signaling and oncogenesis. Interferon regulatory factor 9 (IRF9) is recruited and expressed upon interferon stimulation and is dependent on cofactors that exert in tumor-suppressing or oncogenic functions via the JAK-STAT pathway. IRF9 is frequently overexpressed in human lung cancer and is associated with decreased patient survival; however, the underlying mechanisms remain to be elucidated. Here, we used stably transduced lung adenocarcinoma cell lines (A549 and A427) to overexpress or knockdown
Identifiants
pubmed: 33430083
pii: cancers13020208
doi: 10.3390/cancers13020208
pmc: PMC7827113
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Max Planck Society
ID : .
Organisme : Verein zur Förderung der Krebsforschung in Gieβen e.V
ID : .
Organisme : Von-Behring-Röntgen-Stiftung
ID : .
Organisme : Rhön Klinikum AG grant
ID : .
Organisme : Institute for Lung Health (ILH)
ID : .
Organisme : Cardio-Pulmonary Institute (CPI)
ID : .
Organisme : German Center for Lung Research (DZL)
ID : .
Organisme : DFG, SFB CRC 1213
ID : (Project A01, A05 to Pullamsetti SS and project A10* to Savai R)
Organisme : European Research Council (ERC) Consolidator Grant
ID : (#866051 to Pullamsetti SS)
Références
Genome Biol. 2014;15(12):550
pubmed: 25516281
Am J Respir Crit Care Med. 2015 Feb 15;191(4):437-47
pubmed: 25536148
NPJ Precis Oncol. 2019 Aug 29;3:21
pubmed: 31482136
J Allergy Clin Immunol. 2019 Jul;144(1):309-312.e10
pubmed: 30826365
Mol Cell Biochem. 2020 Sep;472(1-2):125-134
pubmed: 32577948
Nucleic Acids Res. 2020 Jan 24;48(2):589-604
pubmed: 31799619
Trends Mol Med. 2017 Apr;23(4):310-319
pubmed: 28279624
Histol Histopathol. 2013 Jun;28(6):701-13
pubmed: 23519970
Nat Rev Immunol. 2006 Sep;6(9):644-58
pubmed: 16932750
Nat Commun. 2014 Oct 16;5:5160
pubmed: 25319116
Lung Cancer. 2007 Jul;57(1):96-102
pubmed: 17337084
Exp Cell Res. 2018 Apr 15;365(2):185-193
pubmed: 29501566
Cytokine Growth Factor Rev. 2016 Jun;29:71-81
pubmed: 27053489
Gastroenterology. 2006 Jul;131(1):153-64
pubmed: 16831599
Nat Rev Drug Discov. 2019 Mar;18(3):219-234
pubmed: 30679806
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
Biochem Biophys Res Commun. 2018 Dec 9;507(1-4):330-336
pubmed: 30446226
Nat Rev Cancer. 2004 Nov;4(11):839-49
pubmed: 15516957
Nat Med. 2014 Nov;20(11):1289-300
pubmed: 25344740
Cancer Cell. 2014 Jan 13;25(1):37-48
pubmed: 24434209
J Natl Cancer Inst. 2003 Mar 19;95(6):437-48
pubmed: 12644537
Bioinformatics. 2011 Apr 1;27(7):1017-8
pubmed: 21330290
Cancer Res. 2001 Sep 1;61(17):6540-7
pubmed: 11522652
EMBO J. 2013 Oct 16;32(20):2751-63
pubmed: 24065129
Eur J Cancer. 2018 Nov;103:356-387
pubmed: 30100160
J Virol. 2017 Oct 27;91(22):
pubmed: 28878077
Nucleic Acids Res. 2014 Jan;42(Database issue):D191-8
pubmed: 24253303
J Biol Chem. 1998 Aug 14;273(33):21342-51
pubmed: 9694895
Expert Opin Investig Drugs. 2012 Aug;21(8):1107-22
pubmed: 22667993
PLoS One. 2013 Dec 18;8(12):e82241
pubmed: 24367507
Endocr Relat Cancer. 2013 Aug 23;20(5):677-89
pubmed: 23913484
JAKSTAT. 2013 Jul 1;2(3):e23931
pubmed: 24069549
BMC Cancer. 2012 Aug 03;12:341
pubmed: 22862967
Lancet. 2001 Jun 2;357(9270):1777-89
pubmed: 11403834
Int J Cancer. 2015 Feb 15;136(4):E51-61
pubmed: 25156627
Nat Biotechnol. 2020 Jun;38(6):675-678
pubmed: 32444850
Genes Cells. 1996 Jan;1(1):115-24
pubmed: 9078371
PLoS One. 2015 Sep 28;10(9):e0139073
pubmed: 26413839
J Neuropathol Exp Neurol. 1999 Jun;58(6):597-605
pubmed: 10374750
Oncoimmunology. 2012 Nov 1;1(8):1376-1386
pubmed: 23243601
J Clin Invest. 2008 Apr;118(4):1417-26
pubmed: 18340381
CA Cancer J Clin. 2019 Sep;69(5):363-385
pubmed: 31184787
BMC Cancer. 2014 Apr 23;14:283
pubmed: 24758408
Nat Cell Biol. 2016 Jul;18(7):777-89
pubmed: 27323328
Nat Commun. 2019 Jul 2;10(1):2921
pubmed: 31266943
J Cereb Blood Flow Metab. 2019 Jul;39(7):1369-1380
pubmed: 29480757
Methods. 2013 Sep 1;63(1):41-9
pubmed: 23816787
J Immunother. 2009 Oct;32(8):803-16
pubmed: 19752753
Mol Cell. 2010 May 28;38(4):576-89
pubmed: 20513432
Proc Natl Acad Sci U S A. 2018 Jan 23;115(4):E601-E609
pubmed: 29317535
Elife. 2018 Oct 25;7:
pubmed: 30355451
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Nucleic Acids Res. 2015 Jan;43(Database issue):D92-6
pubmed: 25378343
Semin Oncol. 2014 Apr;41(2):156-73
pubmed: 24787290
Annu Rev Immunol. 2008;26:535-84
pubmed: 18303999
Cancer Metastasis Rev. 2009 Jun;28(1-2):233-45
pubmed: 19160015
Histochem J. 1997 Jan;29(1):21-30
pubmed: 9088942
J Biol Chem. 2009 Mar 27;284(13):8596-604
pubmed: 19164294
J Exp Med. 2018 Oct 1;215(10):2567-2585
pubmed: 30143481
Cell Res. 2013 May;23(5):673-90
pubmed: 23545780
Proc Natl Acad Sci U S A. 2018 Apr 10;115(15):3906-3911
pubmed: 29581268
Can J Physiol Pharmacol. 2006 Jan;84(1):77-92
pubmed: 16845893
J Biol Chem. 1994 Dec 30;269(52):32999-3008
pubmed: 7528742
J Interferon Cytokine Res. 2019 Jan;39(1):6-21
pubmed: 29889594